CEA Response and Depth of Response (DpR) to Predict Clinical Outcomes of First-Line Cetuximab Treatment for Metastatic Colorectal Cancer

被引：0
|
作者：
Yu Sunakawa
Akihito Tsuji
Tadamichi Denda
Yoshihiko Segawa
Yuji Negoro
Ken Shimada
Mitsugu Kochi
Masato Nakamura
Masahito Kotaka
Hiroaki Tanioka
Akinori Takagane
Satoshi Tani
Tatsuro Yamaguchi
Takanori Watanabe
Masahiro Takeuchi
Masashi Fujii
Wataru Ichikawa
机构：
[1] St. Marianna University School of Medicine,Department of Clinical Oncology
[2] Kagawa University Faculty of Medicine Cancer Center,Department of Clinical Oncology
[3] Kagawa University Hospital,Division of Gastroenterology
[4] Chiba Cancer Center,Department of Medical Oncology
[5] International Medical Center,Department of Gastroenterology
[6] Saitama Medical University,Division of Medical Oncology, Department of Internal Medicine
[7] Kochi Health Sciences Center,Department of Digestive Surgery
[8] Showa University Koto Toyosu Hospital,Aizawa Comprehensive Cancer Center
[9] Nihon University School of Medicine,Gastrointestinal Cancer Center
[10] Aizawa Hospital,Department of Medical Oncology
[11] Sano Hospital,Department of Surgery
[12] Japan Labour Health and Welfare Organization Okayama Rosai Hospital,Department of Internal Medicine
[13] Hakodate Goryoukaku Hospital,Department of Surgery
[14] Konan Hospital,Department of Surgery
[15] Tokyo Metropolitan Cancer and Infections diseases Center Komagome Hospital,Department of Clinical Medicine (Biostatistics)
[16] Himeji Red Cross Hospital,Division of Medical Oncology
[17] Kitasato University School of Pharmacy,undefined
[18] Showa University Fujigaoka Hospital,undefined
来源：
Targeted Oncology | 2017年 / 12卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：787 / 794
页数：7
相关论文
共 50 条
  • [11] Cetuximab in first line treatment of metastatic colorectal cancer
    Barone, Carlo
    Belisari, Andrea
    Ciardiello, Fortunato
    D'Angiolella, Lucia
    Furneri, Gianluca
    Mantovani, Lorenzo
    Normanno, Nicola
    Piacentini, Patrizio
    Pinto, Carmine
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2012, 13 : 3 - 78
  • [12] Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
    Bokemeyer, Carsten
    Bondarenko, Igor
    Makhson, Anatoly
    Hartmann, Joerg T.
    Aparicio, Jorge
    de Braud, Filippo
    Donea, Serban
    Ludwig, Heinz
    Schuch, Gunter
    Stroh, Christopher
    Loos, Anja H.
    Zubel, Angela
    Koralewski, Piotr
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (05) : 663 - 671
  • [13] COST-EFFECTIVENESS OF CETUXIMAB AS FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER IN THE UNITED STATES
    Ortendahl, J. D.
    Bentley, T. G.
    Anene, A. M.
    Purdum, A. G.
    Bolinder, B.
    VALUE IN HEALTH, 2014, 17 (03) : A86 - A86
  • [14] How do we optimally use cetuximab in first-line treatment for metastatic colorectal cancer?
    Lindsay, Colin R.
    Roxburgh, Patricia
    Graham, Janet
    FUTURE ONCOLOGY, 2013, 9 (06) : 825 - 829
  • [15] Combination of cetuximab and chemotherapy in the first-line treatment of metastatic colorectal cancer: Slovakian experience.
    Salek, T.
    Sebo, E.
    Mazalova, D.
    Chovanec, J.
    Stresko, M.
    Thomkova, A.
    Andrasina, I.
    Barilla, R.
    Hlavata, Z.
    Mego, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [16] Cost-Effectiveness of Cetuximab as First-line Treatment for Metastatic Colorectal Cancer in the United States
    Shankaran, Veena
    Ortendahl, Jesse D.
    Purdum, Anna G.
    Bolinder, Bjorn
    Anene, Ayanna M.
    Sun, Gordon H.
    Bentley, Tanya G. K.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2018, 41 (01): : 65 - 72
  • [17] Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC)
    Heinemann, Volker
    Stintzing, Sebastian
    Modest, Dominik P.
    Giessen-Jung, Clemens
    Michl, Marlies
    Mansmann, Ulrich R.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 (14) : 1927 - 1936
  • [18] Carcinoembryonic antigen kinetics predict response to first-line treatment in metastatic colorectal cancer: Analysis from PRODIGE 9 trial
    Salfati, Delphine
    Huot, Margaux
    Aparicio, Thomas
    Lepage, Come
    Taieb, Julien
    Bouche, Olivier
    Boige, Valerie
    Phelip, Jean-Marc
    Dahan, Laetitia
    Bennouna, Jaafar
    Le Malicot, Karine
    Boussari, Olayide
    Gornet, Jean-Marc
    DIGESTIVE AND LIVER DISEASE, 2023, 55 (06) : 791 - 798
  • [19] Cetuximab plus FOLFIRI as first-line treatment for metastatic colorectal CA.
    Rougier, P
    Raoul, JL
    Van Laethem, JL
    Peeters, M
    Husseini, F
    Brezault, C
    Cals, L
    Vedovato, JC
    Mueser, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 248S - 248S
  • [20] Optimizing the first-line treatment for metastatic colorectal cancer
    Cherri, Sara
    Oneda, Ester
    Zanotti, Laura
    Zaniboni, Alberto
    FRONTIERS IN ONCOLOGY, 2023, 13
12345